Drug Trial Radar · NCT06376942
A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,050
Planned (sponsor's estimate)
Start
Apr 24, 2024
Primary completion
Apr 25, 2025
Study completion Jun 15, 2025
Sponsor
- Lead sponsor
- Post Graduate Institute of Medical Education and Research, ChandigarhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
No study has examined the role of inhaled glycopyrrolate on mucus secretion. We hypothesize that nebulized glycopyrrolate will improve bronchoscopy procedure by effectively suppressing airway mucus secretion, thereby decreasing cough, and thus improving patient comfort during bronchoscopy. In this study, we aim to compare the efficacy of nebulized glycopyrrolate versus nebulized ipratropium in suppression of cough during flexible bronchoscopy.
Conditions
- Subjects Undergoing Flexible Bronchoscopy
Interventions
GlycopyrroniumDrug
Nebulized glycopyrronium 50 mcg
IpratropiumDrug
Nebulized iptratropium 500 mcg
SalineOther
0.9% saline 2 ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cough countTime frame: Intra-procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bronchoscopy suite, PGIMER
Chandigarh, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.